[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![thexcapitalist Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1671992086424432640.png) Oguz O. | 𝕏 Capitalist 💸 [@thexcapitalist](/creator/twitter/thexcapitalist) on x 87.6K followers
Created: 2025-07-14 14:02:07 UTC

X. $NVO

It's dominating the insulin and GLP-1 market worldwide.

The market hammered it down because it thinks $NVO is falling behind $LLY in the competition for the weight-loss market.

They are wrong. 

$NVO weight-loss pipeline is stronger than that of $LLY as its oral GLP-1 is coming early next year, and oral amycretin is coming by 2030.

Its key patents for Ozempic and Wegovy aren't expiring until 2032, meaning they'll keep printing money for at least X more years.

It's attractive at XX times earnings.

![](https://pbs.twimg.com/media/Gv0neRQXEAAAiBo.jpg)

XXXXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1944759314918285376/c:line.svg)

**Related Topics**
[wegovy](/topic/wegovy)
[ozempic](/topic/ozempic)
[$lly](/topic/$lly)
[$nvo](/topic/$nvo)
[stocks healthcare](/topic/stocks-healthcare)
[eli lilly](/topic/eli-lilly)

[Post Link](https://x.com/thexcapitalist/status/1944759314918285376)